AMTURNIDE
LOE ApproachingNDAORALTABLET
Approved
Dec 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AMTURNIDE is an oral tablet small-molecule combination product approved by Novartis in December 2010. The specific indications and mechanism of action are not publicly detailed in available sources, but the product is positioned as a standard oral therapeutic. It represents a traditional pharmaceutical formulation in the small-molecule class.
LOE Approaching
With loss of exclusivity approaching and moderate competitive pressure (30/100), the brand team is likely in transition mode, with shrinking headcount and shift toward generic defense or lifecycle extension strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and an approaching LOE, AMTURNIDE offers limited near-term career expansion opportunities. Professionals assigned to this product should expect defensive strategy roles focused on brand protection, managed care negotiations, and eventual transition to pipeline assets.
Brand ManagerField Sales Representative
Worked on AMTURNIDE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.